Drug intelligence / Profile preview

SGN-624

Development stage: Unknown
Lead developer: SGN Nanopharma
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Topical, Transdermal

Overview

SGN-624 is a topical nanolotion developed by SGN Nanopharma for the management of pain, specifically targeting both inflammatory and neuropathic components. It is a transdermal fixed-dose combination (FDC) consisting of two active pharmaceutical ingredients (APIs) formulated using a proprietary nanolotion technology designed to enhance skin penetration and local efficacy. The product is primarily indicated for post-surgical recovery following knee and hip replacement surgeries. SGN-624 has completed a 48-patient human proof-of-concept study and has received FDA guidance to proceed into Phase 3 clinical trials.

Beyond the preview

Go deeper on SGN-624.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGN-624.

Explore the full profile